BioSpace News Archive

Yisheng BioPharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer.

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced the selection and implementation of the iEnvision medical affairs platform developed by Envision Technology Solutions.

Thermi, an Almirall company, has created an innovative medical exchange and clinical training platform to advance the science of temperature-controlled tissue heating technology and best practices. This includes the launch of thirty-six (36) National Centers of Excellence (COE) sites, Thermi P.R.E.P. National Academy Platform, and a newly organized Medical Affairs organization led by Dr. Tara Margarella.

New IDSA/SHEA Guidelines Highlight Importance of Multistep Algorithm Immunoassay Toxin Testing in C. difficile Diagnosis

Oppenheimer & Co. Inc. (“Oppenheimer”) - a leading wealth manager and investment bank and a subsidiary of Oppenheimer Holdings (NYSE:OPY) - today announced Leland Gershell, M.D., Ph.D. joined the Firm as Managing Director and Senior Analyst on the Life Sciences research team.

Patients in communities across the United States will reap the benefits of 3D mammography with new installations.

Belong Machine-Learning Provides Tailored Digital Education and Support to Patients Navigating the Cancer Treatment Journey

PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced that the Company has been recognized for its diverse and flexible workplace by Forbes and FlexJobs.

McKesson Specialty Health, a division of McKesson Corporation, announced a strategic collaboration with Cryoport, Inc. (NASDAQ: CYRX, CYRXW) designed to further strengthen its robust logistics services to support the delivery of cell and gene therapies to patients at the point of care.

PharmaCyte Biotech, Inc., Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its 6-month study on storage of the frozen encapsulated cells necessary for the determination of an “initial shelf life” has been successfully completed by Austrianova.